Director/PDMR Shareholding Filing

This filing reports a transaction by Pascal Soriot, Chief Executive Officer of AstraZeneca PLC. On September 14, 2026, Mr. Soriot purchased 60,000 ordinary shares of the company at a price of GB£121.02 per share. This transaction is an initial notification made in accordance with the EU Market Abuse Regulation, as it forms part of UK law. The filing provides details of the instrument, nature of the transaction, price, volume, and date. AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, UK, with medicines sold in over 125 countries.